AstraZeneca to pay $125 million upfront for two drug development programmes

AstraZeneca Plc is to pay $125 million upfront for two drug development programmes that address opioid-induced constipation. The payments are part of its exclusive licensing agreement with the US-based Nektar Therapeutics.